4 Mar 2026
Opsoclonus myoclonus syndrome in an HIV patient, following plasmodium falciparum infectionPublisher siteNeurocase, Autoimmune Neurological Disorders and Treatments
Active, last published 2026
In epilepsy research and treatment
Gams Massi
Daniel
Scholar“Research focused on Epilepsy research and treatment and adjacent fields.”
University of Douala
Cameroon
Claim Your ProfileCameroon4
H-index
117
Citations
Gams has not officially claimed their profile. If you are Gams, claim it free.
Claim Your Profile
Pioneer
LOCKED
Pathfinder
LOCKED
Scholar
EARNED
Innovator
LOCKED
Inventor
LOCKED
Catalyst
LOCKED
Expert
UPGRADE
01 · About the work
What I study
ams Massi Daniel is a researcher working on Epilepsy research and treatment. A fuller summary will appear once they update their profile.
02 · Reach
Publication output and reach
Gams's work has been cited 117 times across 2 active years. Bars show publications per year; the line shows cumulative citation totals across publications first appearing in each year.
03 · Research focus
Topics
Epilepsy research and treatment×3Global Health and Surgery×2Genetics, Bioinformatics, and Biomedical Research×2
04 · Where I am
Affiliations
Affiliation on published researchUniversity of Buea, CameroonDrawn from the institution listed on this researcher’s published work.
05 · Selected work
Recent publications
2 works13 Oct 2023Open access4cites
Epilepsy awareness days, weeks, and months: Their roles in the fight against epilepsy and the intersectoral global action plan on epilepsy and other neurological disordersPublisher siteEpilepsy & Behavior, Epilepsy research and treatment
Expert Academic Profiles go further
Citation trend analytics, exportable publication records, and direct enquiry routing from industry and funders.
Are you Gams?
Claim it to verify your details, connect with industry partners, and explore Fractional Domain Expert opportunities through MARATTO™.
African researchers are full of potential that too often goes unrecognised. Your MARATTO™ profile gives your work the commercial pathway it deserves.
Claim Your Profile
Free to claim · takes a minute to verify it’s you